Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ESRRG | P62508 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020144 | 0.99 | DPP4 (0.38) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4019458 | 0.94 | DPP4 (0.35) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4028039 | 0.92 | DPP4 (0.36) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4027949 | 0.91 | KDM2B (0.34) | MC4RMAPTMGLLKDM2BNPSR1 | |
| SCHEMBL4020633 | 0.91 | MEN1 (0.35) | MC4RMGLLKDM2BESRRG | |
| SCHEMBL4778298 | 0.89 | MC4R (0.35) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4022700 | 0.89 | DPP4 (0.34) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4028055 | 0.88 | ALDH1A1 (0.37) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4028057 | 0.88 | ALDH1A1 (0.37) | DPP4DPP8MC4RMAPTALDH1A1 | |
| SCHEMBL4751303 | 0.87 | KDM2B (0.33) | MC4RALDH1A1KDM4EMGLLKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | DPP4 4285/4885DPP8 3973/4885MC4R 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.